Jiangsu Recbio Technology Co., Ltd. (SEHK: 2179)
Health Care · Biotechnology · CN
HK$5.13
+2.60% today · -34.1% 1Y
Jiangsu Recbio Technology Co., Ltd. (SEHK: 2179) operates in the Biotechnology industry within the Health Care sector. The company is valued at $403.22M and employs 491 people.
Over the last twelve months the share price has lost 34.1%, trading between 3.40 and 8.00.
Tweenvest scores Jiangsu Recbio Technology Co., Ltd. across four factors: quality 18/100, value 39/100. Its strongest factor is value.
2179 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $403.22M
- Revenue (TTM)
- $1.82M
- P/E
- —
- EPS
- -1.15
- Dividend yield
- —
- Beta (5Y)
- 0.09
- 52-week high
- HK$8.00
- 52-week low
- HK$3.40
- Avg volume (3M)
- —
- Shares outstanding
- 616.81M
- Employees
- 491
- Next earnings
- —
About Jiangsu Recbio Technology Co., Ltd.
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
- ISIN
- CNE1000057K9
- Founded
- 2011
- Listed since
- Mar 31, 2022
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.15 | -0.14% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.98 | +0.26% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.96 | +0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $549.00 | +0.26% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $834.94 | +0.78% |
| argenx SEENXTBR: ARGX | $63.06B | €872.80 | +1.00% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.09 | +1.58% |
Figures last refreshed Aug 18, 2026.